Department of Arthrosis, The Second Affiliated Hospital of Inner Mongolia Medical University, Huhhot, Inner Mongolia Autonomous Region, China.
Department of Trauma and Orthopedics, Inner Mongolia People's Hospital, Hohhot, Inner Mongolia Autonomous Region, China.
PLoS One. 2022 Nov 4;17(11):e0277269. doi: 10.1371/journal.pone.0277269. eCollection 2022.
Diabetic foot (DF) is one of the most serious chronic complications of diabetes. In recent years, the use of the tibial cortex transverse transport (TTT) technique has enabled great progress in microcirculation reconstruction and achievement of good outcomes in DF treatment. The objective of this systematic review protocol is to evaluate the efficacy and safety of TTT for DF.
Literature search was conducted using the Cochrane Library, Embase, PubMed, Web of Science, China Science Technology Journal Database (VIP), Wanfang Data, China National Knowledge Infrastructure (CNKI), Chinese Biomedical Literature Service System (SinoMed), and Chinese Biomedical Literature Service System (CBM) from inception until March, 1st 2022. In addition, our reviewers will retrieve dissertations, grey literature, systematic reviews, and reference lists of the relevant studies. Randomized controlled trials (RCTs) which compared the TTT for DF with conventional treatment will be included. Our reviewers will perform subgroup analysis, sensitivity analysis, and publication bias analysis to evaluate the heterogeneity and robustness. RevMan 5.3 software and Stata V.16.0 software will be used to analyze the available data.
Ethical approval was not required because this protocol neither collected private information, nor involved animal experiments. The research was disseminated by academic journals or related meetings.
CRD42021279717.
糖尿病足(DF)是糖尿病最严重的慢性并发症之一。近年来,胫骨皮质横向转运(TTT)技术的应用在微循环重建方面取得了重大进展,使 DF 治疗取得了良好的效果。本系统评价方案的目的是评估 TTT 治疗 DF 的疗效和安全性。
检索 Cochrane 图书馆、Embase、PubMed、Web of Science、中国科技期刊数据库(VIP)、万方数据、中国国家知识基础设施(CNKI)、中国生物医学文献服务系统(SinoMed)和中国生物医学文献服务系统(CBM)自成立至 2022 年 3 月 1 日的文献。此外,我们的评审员还将检索论文、灰色文献、系统评价和相关研究的参考文献列表。将纳入比较 TTT 治疗 DF 与常规治疗的随机对照试验(RCT)。我们的评审员将进行亚组分析、敏感性分析和发表偏倚分析,以评估异质性和稳健性。RevMan 5.3 软件和 Stata V.16.0 软件将用于分析可用数据。
本方案不需要伦理批准,因为它既不收集私人信息,也不涉及动物实验。研究将通过学术期刊或相关会议进行传播。
PROSPERO 注册号:CRD42021279717。